The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 8, 2014, Pages 1294-1301

  Eckhardt, C L ^a   Astermark, J ^b   Nagelkerke, S Q ^c   Geissler, J ^c   Tanck, M W T ^a   Peters, M ^a   Fijnvandraat, K ^a   Kuijpers, T W ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SANQUIN RESEARCH   (Netherlands)

Author keywords

Fc gamma receptors; Hemophilia A; Neutralizing antibodies; Risk factors; Single nucleotide polymorphism

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR IIA; GENOMIC DNA; RECEPTOR ANTIBODY; FC RECEPTOR;

ARTICLE; CASE CONTROL STUDY; COPY NUMBER VARIATION; DNA EXTRACTION; FEMALE; GENE CLUSTER; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; GENETICS; IMMUNOLOGY; PATHOPHYSIOLOGY;

ANTIBODY FORMATION; DNA COPY NUMBER VARIATIONS; HEMOPHILIA A; HUMANS; IMMUNITY, CELLULAR; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG;

EID: 84905648933     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12631     Document Type: Article

References (42)

1. Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121: 4046-55.
2. Gouw SC, van der Bom JG, van den Berg MH. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
3. Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M. Diagnosis and management of haemophilia. BMJ 2012; 344: e2707.
4. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
5. Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood 2009; 114: 1423-8.
6. Fulcher CA, de Graaf MS, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-80.
7. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-93.
8. Gouw SC, Fijnvandraat K. identifying nongenetic risk factors for inhibitor development in severe hemophilia A. Semin Thromb Hemost 2013; 39: 740-51.
9. Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG, Margaglione M, Thompson AR, van Heerde W, Boekhorst J, Miller CH, le Cessie S, van der Bom JG. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119: 2922-34.
10. Lozier JN, Rosenberg PS, Goedert JJ, Menashe I. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia 2011; 17: 641-9.
11. Bafunno V, Santacroce R, Chetta M, Peyvandi F, Sessa F, Chinni E, Longo V, Margaglione M. Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A. Haemophilia 2012; 18: 1003-7.
12. Pavlova A, Delev D, Lacroix-Desmazes S, Schwaab R, Mende M, Fimmers R, Astermark J, Oldenburg J. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009; 7: 2006-15.
13. Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
14. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
15. Astermark J, Donfield SM, Gomperts ED, Schwarz J, Menius ED, Pavlova A, Oldenburg J, Kessing B, Dimichele DM, Shapiro AD, Winkler CA, Berntorp E. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013; 121: 1446-54.
16. Lu Y, Ding Q, Dai J, Wang H, Wang X. Impact of polymorphisms in genes involved in autoimmune disease on inhibitor development in Chinese patients with haemophilia A. Thromb Haemost 2012; 107: 30-6.
17. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
18. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 2005; 2: 1-18.
19. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
20. Breunis WB, van Mirre E, Bruin M, Geissler J, de Boer M, Peters M, Roos D, de Haas M, Koene HR, Kuijpers TW. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 2008; 111: 1029-38.
21. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: e57.
22. Koene HR, Kleijer M, Roos D, de Haas M, von dem Borne AE. Fc gamma RIIIB gene duplication: evidence for presence and expression of three distinct Fc gamma RIIIB genes in NA(1+, 2+)SH(+) individuals. Blood 1998; 91: 673-9.
23. de Haas M, Kleijer M, van Zwieten R, Roos D, von dem Borne AE. Neutrophil Fc gamma RIIIb deficiency, nature, and clinical consequences: a study of 21 individuals from 14 families. Blood 1995; 86: 2403-13.
24. Bruin M, Bierings M, Uiterwaal C, Revesz T, Bode L, Wiesman ME, Kuijpers T, Tamminga R, de Haas M. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. Br J Haematol 2004; 127: 561-7.
25. Suktitipat B, Mathias RA, Vaidya D, Yanek LR, Young JH, Becker LC, Becker DM, Wilson AF, Falin MD. The robustness of generalized estimating equations for association tests in extended family data. Hum Hered 2012; 74: 17-26.
26. Breunis WB, van Mirre E, Geissler J, Laddach N, Wolbink G, van der Schoot E, de Haas M, de Boer M, Roos D, Kuijpers TW. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat 2009; 30: E640-50.
27. Hessner MJ, Shivaram SM, Dinauer DM, Curtis BR, Endean DJ, Aster RH. Neutrophil antigen (FcgammaRIIIB) SH gene frequencies in six racial groups. Blood 1999; 93: 1115-6.
28. Dijstelbloem HM, Bijl M, Fijnheer R, Scheepers RH, Oost WW, Jansen MD, Sluiter WJ, Limburg PC, Derksen RH, van de Winkel JG, Kallenberg CG. Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum 2000; 43: 2793-800.
29. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119: 5640-9.
30. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113: 3716-25.
31. Lehrnbecher T, Foster CB, Zhu S, Leitman SF, Goldin LR, Huppi K, Chanock SJ. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 1999; 94: 4220-32.
32. Yee AM, Ng SC, Sobel RE, Salmon JE. Fc gammaRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1180-2.
33. Sanders LA, van de Winkel JG, Rijkers GT, Voorhorst-Ogink MM, de Haas M, Capel PJ, Zegers BJ. Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis 1994; 170: 854-61.
34. Bredius RG, Derkx BH, Fijen CA, de Wit TP, de Haas M, Weening RS, van de Winkel JG, Out TA. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 1994; 170: 848-53.
35. Khor CC, Davila S, Breunis WB, Lee YC, Shimizu C, Wright VJ, Yeung RS, Tan DE, Sim KS, Wang JJ, Wong TY, Pang J, Mitchell P, Cimaz R, Dahdah N, Cheung YF, Huang GY, Yang W, Park IS, Lee JK, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet 2011; 43: 1241-6.
36. Whelan SF, Hofbauer CJ, Horling FM, Allacher P, Wolfsegger MJ, Oldenburg J, Male C, Windyga J, Tiede A, Schwarz HP, Scheiflinger F, Reipert BM. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121: 1039-48.
37. den Dunnen J, Vogelpoel LT, Wypych T, Muller FJ, de Boer L, Kuijpers TW, Zaat SA, Kapsenberg ML, de Jong EC. IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs and FcgammaRIIa in human dendritic cells. Blood 2012; 120: 112-21.
38. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
39. Eckhardt CL, van der Bom JG, van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost 2011; 9: 1948-58.
40. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
41. Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howerd TE. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-27.
42. van der Heijden J, Breunis WB, Geissler J, de Boer M, van den Berg TK, Kuijpers TW. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol 2012; 188: 1318-24.